Literature DB >> 34357833

Economic evaluation of varicella vaccination strategies in Jiangsu province, China: a decision-tree Markov model.

Qiang Wang1,2, Shixin Xiu3, Liuqing Yang1,2, Jinxin Huang1,2, Tingting Cui1,2, Naiyang Shi1,2, Xuwen Wang3, Yuan Shen3, Enpin Chen3, Bing Lu3, Hui Jin1,2, Leesa Lin4,5.   

Abstract

This study evaluated different varicella vaccination strategies in Jiangsu province, China. A decision-tree Markov model was used to evaluate the cost effectiveness of various varicella vaccination strategies for children, including direct and selective vaccination (serotesting pre-vaccination). A cohort of one-year-old children was followed through 60 one-year Markov cycles. The parameter estimation was based on field work, the literature, and statistical yearbooks. We calculated the incremental cost-utility ratio (ICUR) using the saved quality-adjusted life year (QALY). One-way and probability sensitivity analyses were performed to assess uncertainty. Among 100,000 cohort members, one-dose and two-dose direct vaccination averted 8061 and 10,701 varicella cases, respectively, compared with no vaccination. Furthermore, compared with no vaccination, one-dose and two-dose direct vaccination saved one QALY at the ICUR of USD 21,401.33 and USD 35,420.81, respectively, at less than three times the per capita gross domestic product (USD 47,626.86) of Jiangsu. The ICURs of the one-dose and two-dose selective strategies versus no vaccination were USD 42,623.62 and USD 51,406.35 per QALY gained, respectively. The cost effectiveness results were most sensitive to the QALY loss of outpatients and vaccine prices. Thus, in Jiangsu, one-dose and two-dose direct varicella vaccination in children could be cost effective at the willingness to pay threshold of three times provincial GDP per capita from a societal perspective. The findings were sensitive to the vaccine price and health utility of varicella cases.

Entities:  

Keywords:  China; Varicella vaccination; children; cost utility; decision tree model

Mesh:

Year:  2021        PMID: 34357833      PMCID: PMC8828140          DOI: 10.1080/21645515.2021.1958608

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN: 2164-5515            Impact factor:   4.526


  44 in total

1.  Varicella in French adolescents and adults: individual risk assessment and cost-effectiveness of routine vaccination.

Authors:  Thomas Hanslik; Pierre-Yves Boëlle; Michael Schwarzinger; Fabrice Carrat; Kenneth A Freedberg; Alain-Jacques Valleron; Antoine Flahault
Journal:  Vaccine       Date:  2003-09-08       Impact factor: 3.641

2.  Prevention of varicella: Recommendations of the Advisory Committee on Immunization Practices (ACIP). Centers for Disease Control and Prevention.

Authors: 
Journal:  MMWR Recomm Rep       Date:  1996-07-12

Review 3.  Varicella.

Authors:  Ulrich Heininger; Jane F Seward
Journal:  Lancet       Date:  2006-10-14       Impact factor: 79.321

4.  Seeking the optimal schedule for chickenpox vaccination in Canada: Using an agent-based model to explore the impact of dose timing, coverage and waning of immunity on disease outcomes.

Authors:  Ellen R S Rafferty; Wade McDonald; Nathaniel D Osgood; Weicheng Qian; Alexander Doroshenko
Journal:  Vaccine       Date:  2019-11-15       Impact factor: 3.641

Review 5.  Primary versus secondary failure after varicella vaccination: implications for interval between 2 doses.

Authors:  Paolo Bonanni; Anne Gershon; Michael Gershon; Andrea Kulcsár; Vassiliki Papaevangelou; Bernard Rentier; Catherine Sadzot-Delvaux; Vytautas Usonis; Timo Vesikari; Catherine Weil-Olivier; Peter de Winter; Peter Wutzler
Journal:  Pediatr Infect Dis J       Date:  2013-07       Impact factor: 2.129

Review 6.  Varicella prevention in the United States: a review of successes and challenges.

Authors:  Mona Marin; H Cody Meissner; Jane F Seward
Journal:  Pediatrics       Date:  2008-09       Impact factor: 7.124

7.  Cost-effectiveness of varicella serotesting versus presumptive vaccination of school-age children and adolescents.

Authors:  T A Lieu; L J Finkler; M E Sorel; S B Black; H R Shinefield
Journal:  Pediatrics       Date:  1995-05       Impact factor: 7.124

8.  Cost-effectiveness analysis of varicella vaccine as post-exposure prophylaxis in Hong Kong.

Authors:  Ka-Sing Chui; Hiu-Lok Wu; Joyce H S You
Journal:  Scand J Infect Dis       Date:  2013-11-15

Review 9.  Global Varicella Vaccine Effectiveness: A Meta-analysis.

Authors:  Mona Marin; Melanie Marti; Anita Kambhampati; Stanley M Jeram; Jane F Seward
Journal:  Pediatrics       Date:  2016-02-16       Impact factor: 7.124

10.  Cost-effectiveness of community-based screening and treatment for chronic hepatitis B in The Gambia: an economic modelling analysis.

Authors:  Shevanthi Nayagam; Lesong Conteh; Elisa Sicuri; Yusuke Shimakawa; Penda Suso; Saydiba Tamba; Ramou Njie; Harr Njai; Maud Lemoine; Timothy B Hallett; Mark Thursz
Journal:  Lancet Glob Health       Date:  2016-08       Impact factor: 26.763

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.